Methylenetetrahydrofolate reductase C677T polymorphism in Iraqi patients with ischemic stroke

Neurology India

Volumn 57, Issue 5, 2009, Pages 631-634

  Al Allawi, Nasir S ^a   Avo, Arteen S ^a   Jubrael, Jaladet S ^a  

^a UNIVERSITY OF DUHOK   (Iraq)

Author keywords

Homocysteine; Ischemic stroke; Methylenetetrahydrofolate reductase C677 T

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); GLUCOSE; HOMOCYSTEINE; LIPID;

ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COLORIMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; IRAQ; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; SEX DIFFERENCE;

BRAIN ISCHEMIA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOCYSTEINE; HUMANS; IRAQ; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; STROKE;

EID: 72849111860     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.57821     Document Type: Article

References (41)

1. Murry CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997;349:1498-1504
2. Goldstein LB, Adams R, Albert MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke. Stroke 2006;37:1583-1633
3. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in the methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Haematologica 1999;84:824-828
4. Botto L, Yang Q. 5,10-Methyelenetetrahydrofolate reductase gene variants and congenital Anomalies: A HuGE review. Am J Epidemiol 2000;151:862-877
5. Ho CH. Prevalence of Prothrombin 20210A and Methylenetetrahydrofolate reductase C677T genetic mutation in the Chinese population. Ann Haematol 2000;79:239-242
6. Radha Rama Devi A, Govindaiah V, Ramakrishna G, Naushad SM. Prevalence of methylene tetrahydrofolate reductase polymorphism in South Indian population. Current Science 2004;86:440-443
7. Refsum H, Yajnik CS, Gadkari M, Schneede J, Vollset SE, Örning L, et al. Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians. Am J Clin Nutr 2001;74:233-241
8. Hermann W, Obeid R, Jouma M. Hyperhomocysteinemia and vitamin B12 deficiency are more striking in Syrians than Germans - causes and implications. Atherosclerosis 2003;166:143-150
9. Golbahar J, Fathi Z, Tamadon M. Distribution of 5,10 Methylenetetrahydrofolate reductase (C677T) and its association with red blood cell 5-methyltetrahydrofolate in healthy Iranians. Clin Nutr 2005;24:83-87
10. Eid SS, Rihani GR. Prevalence of factor V Leiden, Prothrombin G20210A and MTHFR C677T mutations in 200 Jordanian Healthy individuals. Clin Lab Sci 2004;17:200-202
11. Al-Allawi N, Jubrael J. Thrombophilic mutations in the Dohuk region of Iraq. Proceedings of the 2nd international Jordanian society of pathology conference. Amman, Jordan: 2006.
12. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH, Folsom AR. Risk factors for ischemic stroke subtypes: The atherosclerosis risk in communities study. Stroke s006;37:2493-2498 (Pubitemid 44454667)
13. Dou C, Xia D, Zhang L, Chen X, Flores P, Datta A, Yuan C. Development of a novel enzymatic cycling assay for total homocysteine. Clin Chem 2005;51:1987-1989
14. Hézard N, Cornillet P, Vallade A, Nguyen P. Detection of factor V Leiden using ASO (allele specific oligonucleotide). Thromb Haemost 1997;78:1296.
15. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: Evidence on a causal link from mendelian randomization. Lancet 2005;365:224-232
16. Cronin S, Furie KL, Kelly PJ. Dose-related Association of MTHFR 677T allele with risk of Ischemic stroke: Evidence from a cumulative meta-analysis. Stroke 2005;36:1581-1587
17. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but Methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke. Stroke 2003;34:2085-2090
18. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arteriovasculer Thromb Vasc Biol 1998;18:1465-1469
19. Mukherjee M, Joshi S, Bagadi S, Dalvi M, Rao A, Shetty KR. A low prevalence of the C677T mutation in the methylenetetrahydrofolate reductase gene in Asian Indians. Clin Genet 2002;61:155-159
20. Panigrahi I, Chatterjee T, Biswas A, Behari M, Ved Choudhry P, Saxena R. Role of MTHFR C677T polymorphism in ischemic stroke. Neurol India 2006;54:48-52.
21. Kalita J, Srivastava R, Bansal V, Agarwal S, Misra UK. Methylenetetrahydrofolate reductase gene polymorphism in Indian stroke patients. Neurol India 2006;54:260-263
22. Alluri RV, Mohan V, Komandur S, Chawda K, Chaudhuri JR, Hasan Q. MTHFR C677T gene mutation as a risk for arterial stroke: A hospital based study. Eur J Neurol 2005;12:40-44
23. Wald DS, Law M, Morris JK. Homocysteine and Cardiovascular Disease: Evidence on causality from meta-analysis. BMJ 2002;325:1202-1206 (Pubitemid 35398783)
24. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in Methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113
25. Yoo JH, Chung CS, Kang SS. Relation of plasma homocysteine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478.
26. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG, et al. Prospective study of serum total homcysteine concentration and risk of stoke in middle aged British men. Lancet 1995;346:1395-1398
27. Bostom AG, Rosenberg IH, Silbershatz H,Jacques PF, Selhub J, D'Agostino RB, et al. Non fasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Intern Med 1999;131:352-355
28. Iso H, Moriyamam Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, et al. Serum total homocysteine concentration and risk of stroke and its subtypes in Japanese. Circulation 2004;8:2766-2772
29. Modi M, Prabhakar S, Majumdar S, Khullar M, Das CP. Hyperhomocysteinemia as a risk factor for ischemic stroke: An India scenario. Neurol India 2005;53:297-301.
30. Dudman NP. An alternative view of homocysteine. Lancet 1999;354:2072-2074
31. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated of nitrogen endothelium derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;9:308-318
32. Daradik R, Varon D, Tamarin I, Zivelin A, Salomon O, Shenkman B, et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells underflow conditions: Distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000;83:338-344
33. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle growth by homocysteine: A link of atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-6373
34. Schreiner PJ, Wu KK, Malinow MR, Stinson VL, Szklo M, Nieto FJ, et al. Hyperhomocyst(e)inemia and homeostatic factors: The atherosclerosis risk in communities study. Ann Epidemiol 2002;12:228-236
35. Wald DS, Bishop L, Wald NJ. Randomized trial of folic acid supplementation on serum homocysteine level. Arch Intern Med 2001;161:695-700.
36. Mark SD, Wang W, Fraumeni F Jr, Li JY, Taylor PR, Wang GQ, et al. Lowered risk of hypertension and cerebrovascular disease after vitamin/ mineral supplementation: The Linxian nutrition intervention trial. Am J Epidemiol 1996;143:658-664
37. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: The vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575
38. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Eng J Med 2006;354:1567-1577
39. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, et al. Improvement in stroke mortality in Canada and united states: 1990 to 2002. Circulation 2006;113:1335-1343
40. Murthy JM. Hyperhomocysteinemia, ischemic stroke, and B-vitamin treatment: The jury is still out. Neurol India 2005;53:271-272
41. Ueland PM, Clarke R. Homocysteine and cardiovascular risk: Considering the evidence in the context of study design, folate fortification, and statistical power. Clin Chem 2007;53:807-809